This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Takeda says Meijer can't get quick appeal in US antitrust case over Amitiza

( March 18, 2025, 22:31 GMT | Official Statement) -- MLex Summary: Takeda Pharmaceuticals opposed Meijer’s request for leave to immediately appeal an order in a US antitrust case over Amitiza, saying certification of the arbitration order for interlocutory appeal would contradict the Federal Arbitration Act’s express prohibition against “granting a stay of any action under section 3 [or] directing arbitration to proceed under section 4” of the FAA.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections